EQT Life Sciences and Nextech Invest Ltd are leading Tubulis’ current financing round. Additionally, numerous existing investors such as Bayern Kapital, Biomedpartners, Coparion, the High-Tech Gründerfonds (HTGF), Occident and Seventure Partners are participating. Two new US-based capital providers are also part of the round: Frazier Life Sciences and Deep Track Capital.
The biotech develops so-called antibody-drug conjugates (ADCs) that can attack cancer cells more specifically than before without damaging surrounding tissue. The active substance is combined with an antibody that is capable of distinguishing cancer cells from healthy cells. This allows ADCs to fight cancer not only more precisely and efficiently, but also significantly reduce the side effects of therapy. Previous ADCs often lost a large portion of their active ingredients before reaching the tumor cell. Tubulis’ ADCs deliver these more reliably to their target.
Tubulis plans to use the proceeds from the current financing round to complete the first clinical evaluation of both lead ADC candidates TUB-030 and TUB-040. Additionally, the funds will flow into the further development of Tubulis’ technology platform for developing additional, flexibly adaptable ADC variants. In parallel with the entry of the new US investors, the startup also plans to expand its corporate presence by establishing a US subsidiary.
“The current financing round by various international investors specializing in the biotech segment once again underscores Tubulis’ unique positioning in the ADC space. Our proprietary platform technology and our expertise form the foundation for a pipeline of specialized protein-drug conjugates,”
says Dominik Schumacher, CEO and co-founder of Tubulis.
“Our goal is to establish Tubulis as a globally leading company in ADC development. Our next step will be to complete the clinical phase to unlock the full potential and therapeutic value of ADCs.”
